🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 99 of 151

  1. Permethrin Foam 4%

    VYNE Therapeutics

    Scabies

    phase 2 small molecule completed

    1 trial

  2. Pevonedistat

    Takeda

    Myelodysplastic Syndromes (MDS)

    phase 2 small molecule terminated

    1 trial

  3. Pevonedistat

    Takeda

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    2 trials

  4. Pexastimogene Devacirepvec (Pexa-Vec)

    Regeneron UK Limited

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  5. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials

  6. Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

    Pyxis Oncology

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  7. Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    advanced solid tumors

    phase 2 other active

    1 trial

  8. Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.

    Fondazione Telethon ETS

    metastatic colorectal cancer

    phase 2 other active

    1 trial

  9. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  10. Phase 1b: APG-115+pembrolizumab

    Ascentage Pharma Group

    Unresectable or Metastatic Melanoma or Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  11. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  12. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  13. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  14. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  15. Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  16. Phase I Study of PM534 to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advances solid tumors

    phase 2 other active

    1 trial

  17. Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  18. Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    Pierre Fabre Medicament

    locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    phase 2 other active

    1 trial

  19. Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA.

    Esteve Pharmaceuticals

    Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

    phase 2 other active

    1 trial

  20. Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

    The George Institute

    Malignant Peritoneal Mesothelioma

    phase 2 other active

    1 trial

  21. Phenoptin

    BioMarin Pharmaceutical Australia Pty Ltd

    Tetrahydrobiopterin Deficiencies

    phase 2 small molecule completed

    1 trial

  22. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  23. Piclidenoson

    Can-Fite BioPharma

    COVID-19

    phase 2 small molecule completed

    1 trial

  24. Piclidenoson

    Can-Fite BioPharma

    Lowe Syndrome

    phase 2 small molecule active

    1 trial

  25. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  26. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  27. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  28. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  29. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  30. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  31. Pimavanserin Capsules 10 mg, Pimavanserin 34 mg Capsule, Pimavanserin 20 mg Capsule

    Lacuna Pharma Pty Ltd

    Irritability associated with autistic disorder in children and adolescents with ASD

    phase 2 small molecule active

    1 trial

  32. Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]

    Acadia Pharmaceuticals B.V.

    Autism Spectrum Disorder

    phase 2 small molecule active

    1 trial

  33. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  34. Pimavanserina 34 mg placebo cápsulas, Pimavanserin tartrate

    The George Institute

    Major depressive disorder

    phase 2 small molecule active

    1 trial

  35. Pioglitazone

    Takeda

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  36. Pioglitazone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    1 trial

  37. Pioglitazone

    Takeda

    Inflammation

    phase 2 small molecule completed

    1 trial

  38. Pioglitazone

    Takeda

    Oxidative Stress

    phase 2 small molecule completed

    1 trial

  39. Pioglitazone

    Takeda

    Chronic Pancreatitis

    phase 2 small molecule completed

    1 trial

  40. Pioglitazone and atorvastatin

    Takeda

    Cardiovascular Diseases

    phase 2 small molecule completed

    1 trial

  41. Pioglitazone and azilsartan

    Takeda

    Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  42. Piqray 50 mg and 200 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    metasatic breast cancer, hormon positive, her 2 negative

    phase 2 small molecule active

    1 trial

  43. Pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  44. Pirfenidone

    United Therapeutics Europe Ltd

    Cardiac Failure

    phase 2 small molecule completed

    1 trial

  45. Pirfenidone Solution for Inhalation

    Lacuna Pharma Pty Ltd

    Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  46. Pirfenidone Solution for Inhalation

    Lacuna Pharma Pty Ltd

    Progressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [IPF]

    phase 2 small molecule active

    1 trial

  47. Pirfenidone Solution for Inhalation, Pirfenidone Solution for Inhalation, Placebo for AP01

    Lacuna Pharma Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  48. Piromelatine (Neu-P11)

    Lacuna Pharma Pty Ltd

    idiopathic (isolated) Rapid Eye Movement Behavior Disorder

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.